You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

VEVYE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Vevye patents expire, and what generic alternatives are available?

Vevye is a drug marketed by Harrow Eye and is included in one NDA. There are five patents protecting this drug.

This drug has eighty-five patent family members in nineteen countries.

The generic ingredient in VEVYE is cyclosporine. There are eighteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vevye

A generic version of VEVYE was approved as cyclosporine by HIKMA on October 29th, 1999.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VEVYE?
  • What are the global sales for VEVYE?
  • What is Average Wholesale Price for VEVYE?
Summary for VEVYE
International Patents:85
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Drug Prices: Drug price information for VEVYE
What excipients (inactive ingredients) are in VEVYE?VEVYE excipients list
DailyMed Link:VEVYE at DailyMed
Drug patent expirations by year for VEVYE
Drug Prices for VEVYE

See drug prices for VEVYE

US Patents and Regulatory Information for VEVYE

VEVYE is protected by five US patents and one FDA Regulatory Exclusivity.

Patents protecting VEVYE


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF DRY EYE DISEASE (DED)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting VEVYE

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Harrow Eye VEVYE cyclosporine SOLUTION;OPHTHALMIC 217469-001 May 30, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Harrow Eye VEVYE cyclosporine SOLUTION;OPHTHALMIC 217469-001 May 30, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Harrow Eye VEVYE cyclosporine SOLUTION;OPHTHALMIC 217469-001 May 30, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Harrow Eye VEVYE cyclosporine SOLUTION;OPHTHALMIC 217469-001 May 30, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Harrow Eye VEVYE cyclosporine SOLUTION;OPHTHALMIC 217469-001 May 30, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Harrow Eye VEVYE cyclosporine SOLUTION;OPHTHALMIC 217469-001 May 30, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VEVYE

See the table below for patents covering VEVYE around the world.

Country Patent Number Title Estimated Expiration
Japan 2013513586 ⤷  Sign Up
Poland 2512515 ⤷  Sign Up
Japan 6731039 ⤷  Sign Up
Denmark 3722274 ⤷  Sign Up
Australia 2019358249 Ophthalmic composition for treatment of dry eye disease ⤷  Sign Up
South Korea 20190057338 시클로스포린을 포함하는 안과 조성물 ⤷  Sign Up
South Korea 101652714 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VEVYE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2049079 LUC00006 Luxembourg ⤷  Sign Up PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.